Post-Market Study of JUVÉDERM VOLIFT™ With Lidocaine for the Correction of Nasolabial Folds

A prospective, open-label, multi-center, observational, post-market study evaluating JUVÉDERM VOLIFT™ for the correction of moderate to severe nasolabial folds

Study Overview

• Status: Completed
• Conditions: Moderate to Severe Nasolabial Folds
• Intervention / Treatment: Device: Crosslinked hyaluronic acid dermal filler

• Study Type: Interventional
• Enrollment (Actual): 70
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Germany
  • Darmstadt, Germany
  • Koln, Germany
• Netherlands
  • Naarden, Netherlands

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Male or female 18 years of age or older
• Have 2 fully visible, approximately symmetrical nasolabial folds and has severity scores of 2 or 3 on the 5-point photographic nasolabial fold severity scale (range 0-4) for both nasolabial folds, as judged by the Investigator
• Have a reasonable expectation for correction by injection via deep dermis, as described in the protocol
• Agree to refrain from undergoing other anti-wrinkle/volumizing treatments in the lower two-thirds of the face (below the orbital rim) for the duration of the study
• Understand and be willing to follow all aspects of the study protocol and have signed and dated the Informed Consent prior to any study-related procedures being performed
• Be in good health as in the opinion of the Investigator

Exclusion Criteria:

• Has undergone cosmetic facial procedures (e.g., face lift or other surgeries) which may alter the appearance of the nasolabial fold area
• Cosmetic injections in the lower two-thirds of the face (below the orbital rim), within 6 months prior to entry in the study, or be planning to undergo any of these procedures at any time during the study. NOTE: Prior treatment with HA fillers and/or collagen is allowed, provided the treatment was administered more than 6 months prior to study entry
• Has undergone volumizing of the mid/lower face within 9 months prior to study entry
• Has ever received semi-permanent fillers or permanent facial implants (e.g., calcium hydroxylapatite, poly-L-lactic acid, polymethylmethacrylate, silicone, expanded poly-tetrafluoroethylene) anywhere in the lower face (below the orbital rim), or be planning to be implanted with any of these products at any time during the study
• Have a history of anaphylaxis, multiple severe allergies, atopy, allergy to lidocaine (an any amide-based anesthetics), HA products, or Streptococcal protein, or be planning to undergo a desensitization therapy during the term of the study
• Be a pregnant female, lactating, or planning to become pregnant at any time during the study
• Be a female of childbearing potential not using a reliable means of contraception
• Have received any investigational product within 30 days prior to study enrollment or be planning to participate in another investigation during the course of this study
• Suffer from an uncontrolled personality disorder (e.g., body dysmorphia, depression)
• Have a history of or currently suffer from autoimmune disease (e.g., rheumatoid arthritis, Crohn's disease)
• Have a history of streptococcal disease (e.g., strep throat or rheumatic fever with or without heart complications)
• Have a history of skin cancer
• Suffer from porphyria
• Have epilepsy, which is not controlled by anti-epilepsy therapy
• Current cutaneous inflammatory and/or infectious processes (e.g., acne, herpes)
• Have a history of treatment with interferon
• Be on an ongoing regimen of anti-coagulation therapy (e.g., warfarin) or have taken non-steroidal anti-inflammatory drugs (NSAIDs) (e.g., aspirin, ibuprofen) or other substances known to increase coagulation time (e.g., herbal supplements with garlic or ginkgo biloba) within 10 days of undergoing study device injection. NOTE: Study device injection may be delayed as necessary to accommodate this 10-day period
• Be on a concurrent regimen of high doses of lidocaine (more than 400 mg) which may cause acute toxic reactions
• Be on a concurrent regimen of other local anesthetics structurally related to amide-type local anesthetics
• Have impaired cardiac conduction, severely impaired hepatic function, or severe renal dysfunction
• Have a condition or be in a situation that, in the Investigator's opinion, may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: JUVÉDERM VOLIFT™; All subjects receiving treatment with JUVÉDERM VOLIFT™.	Device: Crosslinked hyaluronic acid dermal filler; All treatment details are at the discretion of the Investigator and should be guided by the Directions for Use. Up to 3 treatments will be administered: Initial treatment, optional top-up treatment at Day 14 post-initial treatment, and optional repeat treatment at Month 12 post-initial treatment.; Other Names: JUVÉDERM VOLIFT™

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Investigator Assessment of Nasolabial Fold Severity Using the 5-point Nasolabial Fold Severity Scale (NLFSS)	Nasolabial fold severity is evaluated by the Investigator on the 5-point NLFSS on both the right and left sides. Scores are assessed as 1 (none), 2 (mild), 3 (moderate), 4 (severe), and 5 (extreme).	Month 12

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Investigator Assessment of Nasolabial Fold Severity Using the 5-point NLFSS	Nasolabial fold severity is evaluated by the Investigator on the 5-point NLFSS on both the right and left sides. Scores are assessed as 1 (none), 2 (mild), 3 (moderate), 4 (severe), and 5 (extreme).	Day 0, Day 14, Month 1, Month 9
Investigator Satisfaction With Aesthetic Outcome on an 11-Point Scale	Investigator satisfaction with aesthetic outcome is assessed on an 11-point scale. Scores range from -5 (definitely not satisfied), 0 (don't know/unsure), and 5 (definitely satisfied).	Day 14, Month 1, Month 9, Month 12
Investigator Assessment of Ease of Injection Use on a 10-Point Scale	Investigator assessment of ease of injection use is assessed on a 10-point scale. Scores range from 0 (easy) to 10 (hard).	Day 0, Day 14
Subject Assessment of Nasolabial Fold Severity Using the 5-point NLFSS	Nasolabial fold severity is evaluated by the subject on the 5-point NLFSS on both the right and left sides. Scores are assessed as 1 (none), 2 (mild), 3 (moderate), 4 (severe), and 5 (extreme).	Day 0, Day 14, Month 1, Month 9, Month 12
Subject Satisfaction With Aesthetic Outcome on an 11-Point Scale	Subject satisfaction with aesthetic outcome is assessed on an 11-point scale. Scores range from -5 (definitely not satisfied), 0 (don't know/unsure), and 5 (definitely satisfied).	Day 14, Month 1, Month 9, Month 12
Subject Assessments of Pain, Swelling, and Bruising Intensity on an 11-Point Scale	Subject assessment of pain, swelling and bruising intensity on an 11-point scale. Scores range from 0 (No pain/swelling/bruising) to 10 (worst pain/swelling/bruising imaginable).	Day 0, Day 14, Month 12, Month 12.5

Collaborators and Investigators

• Sponsor: Allergan

Publications and helpful links

General Publications

• Sattler G, Philipp-Dormston WG, Van Den Elzen H, Van Der Walt C, Nathan M, Kolodziejczyk J, Kerson G, Dhillon B. A Prospective, Open-Label, Observational, Postmarket Study Evaluating VYC-17.5L for the Correction of Moderate to Severe Nasolabial Folds Over 12 Months. Dermatol Surg. 2017 Feb;43(2):238-245. doi: 10.1097/DSS.0000000000000939.

Study record dates

Study Major Dates

• Study Start (Actual): June 1, 2012
• Primary Completion (Actual): March 6, 2014
• Study Completion (Actual): March 6, 2014

Study Registration Dates

• First Submitted: September 4, 2012
• First Submitted That Met QC Criteria: September 4, 2012
• First Posted (Estimate): September 7, 2012

Study Record Updates

• Last Update Posted (Actual): April 16, 2019
• Last Update Submitted That Met QC Criteria: April 3, 2019
• Last Verified: April 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Immunologic Factors; Protective Agents; Adjuvants, Immunologic; Viscosupplements; Hyaluronic Acid
• Other Study ID Numbers: MAF/AGN/MED/FIL/018